-
CheckOrphan NewsFlash, March 2,…
3/02/2010
CheckOrphan NewsFlash for Tuesday, March 2, 2010: breaking news about rare diseases, orphan diseases, orphan drugs, and…
-
CheckOrphan NewsFlash January 15,…
1/15/2010
CheckOrphan NewsFlash for Friday, January 15, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
-
CheckOrphan NewsFlash January 11,…
1/11/2010
CheckOrphan NewsFlash for Monday, January 11, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
NewsFlash
-
ICORD 2010: Sixth International…
18–20 March, 2010
The VI International Conference on Rare Diseases and Orphan Drugs (ICORD…
-
Improving Musculoskeletal Outcomes…
7–9 April, 2010
The goals of this workshop are to (1) assess the state of knowledge…
-
Third NIH Workshop on Gaucher…
8–9 April, 2010
Workshop goals are to (1) determine the appropriate human, animal, or cell…
-
2010 International Research…
9–11 April, 2010
The broad objectives for the 2010 LAM Research Conference are to review…
Events
-
New Data Demonstrates Abbott's Investigational MitraClip(R) System Has Potential to Be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
Monday, March 15, 2010
ATLANTA -- Late-breaking data presented today at the American College of Cardiology's 59th annual scientific session from the landmark EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) trial demonstrated that Abbott's investigational MitraClip(R) system met both its primary safety and At o
-
Abbott Seeks FDA Approval of a New Six-Month 45-Mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer
Monday, March 15, 2010
ABBOTT PARK, Ill. -- The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron® Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancerP
-
Brain Science Institute Announces License Agreement to Develop Treatments for Neurological Disease
Monday, March 15, 2010
Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitorsThe NeuroTranslational Program was launc
-
New Clues About the Basis of Muscle Wasting Disease
Monday, March 15, 2010
New findings that shed light on how genetic damage to muscle cell proteins can lead to the development of the rare muscle-wasting disease, nemaline myopathy, are reported today (15 March) in the Biochemical JournalProfessor Laura Machesky and colleagues from the CRUK Beatson Institute for Cancer R
-
Pancreatic Cancer Study Reveals Mechanism Initiating Disease, in Mice
Monday, March 15, 2010
UCSF scientists have discovered how a mutated gene known as Kras is able to hijack mouse cells damaged by acute pancreatitis, putting them on the path to becoming pancreatic cancer cellsThe finding, they say, suggests one way in which the mutated gene -- found in nearly all cases of the most commo
-
FDA Approves Watson's TRELSTAR(R), the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
Monday, March 15, 2010
MORRISTOWN, N.J. -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the U.S. Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative W
-
FDA Approves Five-Day Dosing Regimen for Dacogen(R) (Decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)
Monday, March 15, 2010
WOODCLIFF LAKE, N.J. -- Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of
-
Mesothelioma That Killed Merlin Olsen Tough to Beat
Friday, March 12, 2010
SALT LAKE CITY -- Merlin Olsen passed away Wednesday from mesothelioma, but a doctor has given tips on how to fight the lung disease that took the U.S.U. football star's lifeWhen a tumor invades, the lungs become unable to absorb fluid in the chest cavity. The fluid build-up causes pressure in th
-
Roche Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
Friday, March 12, 2010
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in T
-
Ulcerative Colitis Product Granted Reimbursement in Sweden
Friday, March 12, 2010
Ulcerative colitis (UC) is a form of inflammatory bowel disease characterized by a chronic inflammation often with ulcers in the large intestineThe symptoms of UC can differ between patients in terms of frequency and severity. The amount of the large intestine affected by UC also varies between pa
